<p>Total Clarity Wealth Management Inc. 在最近向证券交易委员会提交的 13F 表格中表示，在第四季度购买了 Abivax SA Sponsored ADR (NASDAQ:ABVX - 免费报告) 的新股份。该基金购买了 9,245 股公司股票，价值约为 1,247,000 美元。</p>
<p>其他一些机构投资者也调整了他们对 ABVX 的持股。EverSource Wealth Advisors LLC 在第三季度将其在 Abivax 的持股增加了 4,612.5%。EverSource Wealth Advisors LLC 目前拥有 377 股公司股票，价值 32,000 美元，在此期间又购买了 369 股。First Horizon Corp 在第三季度以约 36,000 美元的价格收购了 Abivax 的新股份。美国银行公司 DE 在第四季度将其在 Abivax 的持股增加了 56.1%。美国银行公司 DE 目前拥有 5,536 股公司股票，价值 41,000 美元，在此期间又购买了 1,990 股。Hantz Financial Services Inc. 在第三季度以约 52,000 美元的价格收购了 Abivax 的新股份。最后，WPG Advisers LLC 在第四季度将其在 Abivax 的持股增加了 125.9%。WPG Advisers LLC 目前拥有 454 股公司股票，价值 61,000 美元，在此期间又购买了 253 股。机构投资者和对冲基金持有公司 47.91% 的股份。</p>
<h2>Abivax 股票表现</h2>
<p>Abivax 股票在周五开盘价为 117.38 美元。该公司的市值为 93.1 亿美元，市盈率为 -21.86，贝塔值为 1.68。Abivax SA Sponsored ADR 的 52 周低点为 5.59 美元，52 周高点为 148.83 美元。该股票的 50 日移动平均线为 117.02 美元，200 日移动平均线为 116.30 美元。</p>
<p>Abivax (NASDAQ:ABVX - 获取免费报告) 最近在 2 月 14 日星期六发布了其财报。公司报告该季度每股收益为 -1.20 美元。该业务在该季度的收入为 52 万美元。作为一个整体，卖方分析师预测 Abivax SA Sponsored ADR 在当前财政年度将发布 -3.84 的每股收益。</p>
<h2>华尔街分析师观点</h2>
<p>一些研究分析师最近对该公司发布了报告。Weiss Ratings 在 4 月 20 日的报告中重新发布了对 Abivax 股票的 &#34;卖出 (d-)&#34; 评级。花旗集团在 1 月 8 日的报告中重新发布了对 Abivax 股票的 &#34;市场表现优于大盘&#34; 评级。Oppenheimer 在 1 月 8 日的报告中对 Abivax 设定了 131.00 美元的目标价。BTIG Research 在 2 月 25 日的报告中重新发布了 &#34;买入&#34; 评级，并对 Abivax 股票设定了 150.00 美元的目标价。最后，Jefferies Financial Group 在 3 月 16 日的报告中开始覆盖 Abivax。他们对该股票发布了 &#34;买入&#34; 评级，并设定了 160.00 美元的目标价。一位研究分析师对该股票给予了强烈买入评级，十三位分析师给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat，该公司目前的平均评级为 &#34;适度买入&#34;，平均目标价为 137.15 美元。</p>
<p><strong>阅读我们对 Abivax 的最新分析</strong></p>
<h2>Abivax 公司简介</h2>
<p>(免费报告)</p>
<p>Abivax 成立于 2013 年，总部位于法国巴黎，是一家临床阶段的生物制药公司，专注于发现和开发针对慢性炎症性疾病和病毒感染的新疗法。该公司的技术平台针对宿主 RNA 生物发生，以调节关键免疫通路，提供一种旨在疾病修饰和改善安全性特征的差异化方法。</p>
<p>Abivax 的主要临床资产 obefazimod (ABX464) 正在评估用于溃疡性结肠炎和其他炎症性疾病。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票超过 Abivax</li>
</ul>
<p><strong>想看看其他对冲基金持有的 ABVX 吗？</strong> 访问 HoldingsChannel.com 获取 Abivax SA Sponsored ADR (NASDAQ:ABVX - 免费报告) 的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJWWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJWWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Abivax 吗？</h2>
<p>在你考虑 Abivax 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买... 而 Abivax 并不在名单上。</p>
<p>虽然 Abivax 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

ABVX

标普生物技术 3 倍做多 - Direxion

医疗业 ETF - Vanguard

<p>Total Clarity Wealth Management Inc. 在第四季度收购了 9,245 股 Abivax SA 赞助的 ADR（NASDAQ:ABVX），价值约为 125 万美元。其他机构投资者也增加了对 Abivax 的持股，其中 EverSource Wealth Advisors 和美国银行（Bank of America Corp DE）的增持尤为显著。Abivax 的股票开盘价为 117.38 美元，市值为 93.1 亿美元，市盈率为 -21.86。分析师对该股票的评级不一，平均目标价为 137.15 美元</p>

<p>Total Clarity Wealth Management Inc. bought a new stake in Abivax SA Sponsored ADR (NASDAQ:ABVX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities &amp; Exchange Commission. The fund bought 9,245 shares of the company's stock, valued at approximately $1,247,000.</p>
<div class="lb-trans"><p>Total Clarity Wealth Management Inc. 在最近向证券交易委员会提交的 13F 表格中表示，在第四季度购买了 Abivax SA Sponsored ADR (NASDAQ:ABVX - 免费报告) 的新股份。该基金购买了 9,245 股公司股票，价值约为 1,247,000 美元。</p>
</div><p>A number of other institutional investors have also modified their holdings of ABVX. EverSource Wealth Advisors LLC increased its holdings in shares of Abivax by 4,612.5% in the third quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company's stock valued at $32,000 after purchasing an additional 369 shares during the period. First Horizon Corp acquired a new position in shares of Abivax in the third quarter valued at approximately $36,000. Bank of America Corp DE increased its holdings in shares of Abivax by 56.1% in the fourth quarter. Bank of America Corp DE now owns 5,536 shares of the company's stock valued at $41,000 after purchasing an additional 1,990 shares during the period. Hantz Financial Services Inc. acquired a new position in shares of Abivax in the third quarter valued at approximately $52,000. Finally, WPG Advisers LLC increased its holdings in shares of Abivax by 125.9% in the fourth quarter. WPG Advisers LLC now owns 454 shares of the company's stock valued at $61,000 after purchasing an additional 253 shares during the period. Institutional investors and hedge funds own 47.91% of the company's stock.</p>
<div class="lb-trans"><p>其他一些机构投资者也调整了他们对 ABVX 的持股。EverSource Wealth Advisors LLC 在第三季度将其在 Abivax 的持股增加了 4,612.5%。EverSource Wealth Advisors LLC 目前拥有 377 股公司股票，价值 32,000 美元，在此期间又购买了 369 股。First Horizon Corp 在第三季度以约 36,000 美元的价格收购了 Abivax 的新股份。美国银行公司 DE 在第四季度将其在 Abivax 的持股增加了 56.1%。美国银行公司 DE 目前拥有 5,536 股公司股票，价值 41,000 美元，在此期间又购买了 1,990 股。Hantz Financial Services Inc. 在第三季度以约 52,000 美元的价格收购了 Abivax 的新股份。最后，WPG Advisers LLC 在第四季度将其在 Abivax 的持股增加了 125.9%。WPG Advisers LLC 目前拥有 454 股公司股票，价值 61,000 美元，在此期间又购买了 253 股。机构投资者和对冲基金持有公司 47.91% 的股份。</p>
</div><h2>Abivax Stock Performance</h2>
<div class="lb-trans"><h2>Abivax 股票表现</h2>
</div><p>Abivax stock opened at $117.38 on Friday. The firm has a market capitalization of $9.31 billion, a price-to-earnings ratio of -21.86 and a beta of 1.68. Abivax SA Sponsored ADR has a fifty-two week low of $5.59 and a fifty-two week high of $148.83. The stock's fifty day moving average is $117.02 and its two-hundred day moving average is $116.30.</p>
<div class="lb-trans"><p>Abivax 股票在周五开盘价为 117.38 美元。该公司的市值为 93.1 亿美元，市盈率为 -21.86，贝塔值为 1.68。Abivax SA Sponsored ADR 的 52 周低点为 5.59 美元，52 周高点为 148.83 美元。该股票的 50 日移动平均线为 117.02 美元，200 日移动平均线为 116.30 美元。</p>
</div><p>Abivax (NASDAQ:ABVX - Get Free Report) last posted its earnings results on Saturday, February 14th. The company reported ($1.20) earnings per share for the quarter. The business had revenue of $0.52 million during the quarter. As a group, sell-side analysts forecast that Abivax SA Sponsored ADR will post -3.84 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Abivax (NASDAQ:ABVX - 获取免费报告) 最近在 2 月 14 日星期六发布了其财报。公司报告该季度每股收益为 -1.20 美元。该业务在该季度的收入为 52 万美元。作为一个整体，卖方分析师预测 Abivax SA Sponsored ADR 在当前财政年度将发布 -3.84 的每股收益。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>A number of research analysts have recently issued reports on the company. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Abivax in a report on Monday, April 20th. Citigroup reissued a &#34;market outperform&#34; rating on shares of Abivax in a report on Thursday, January 8th. Oppenheimer set a $131.00 target price on Abivax in a report on Thursday, January 8th. BTIG Research reissued a &#34;buy&#34; rating and issued a $150.00 target price on shares of Abivax in a report on Wednesday, February 25th. Finally, Jefferies Financial Group assumed coverage on Abivax in a report on Monday, March 16th. They issued a &#34;buy&#34; rating and a $160.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $137.15.</p>
<div class="lb-trans"><p>一些研究分析师最近对该公司发布了报告。Weiss Ratings 在 4 月 20 日的报告中重新发布了对 Abivax 股票的 &#34;卖出 (d-)&#34; 评级。花旗集团在 1 月 8 日的报告中重新发布了对 Abivax 股票的 &#34;市场表现优于大盘&#34; 评级。Oppenheimer 在 1 月 8 日的报告中对 Abivax 设定了 131.00 美元的目标价。BTIG Research 在 2 月 25 日的报告中重新发布了 &#34;买入&#34; 评级，并对 Abivax 股票设定了 150.00 美元的目标价。最后，Jefferies Financial Group 在 3 月 16 日的报告中开始覆盖 Abivax。他们对该股票发布了 &#34;买入&#34; 评级，并设定了 160.00 美元的目标价。一位研究分析师对该股票给予了强烈买入评级，十三位分析师给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat，该公司目前的平均评级为 &#34;适度买入&#34;，平均目标价为 137.15 美元。</p>
</div><p><strong>Read Our Latest Analysis on Abivax</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 Abivax 的最新分析</strong></p>
</div><h2>Abivax Company Profile</h2>
<div class="lb-trans"><h2>Abivax 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.</p>
<div class="lb-trans"><p>Abivax 成立于 2013 年，总部位于法国巴黎，是一家临床阶段的生物制药公司，专注于发现和开发针对慢性炎症性疾病和病毒感染的新疗法。该公司的技术平台针对宿主 RNA 生物发生，以调节关键免疫通路，提供一种旨在疾病修饰和改善安全性特征的差异化方法。</p>
</div><p>Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.</p>
<div class="lb-trans"><p>Abivax 的主要临床资产 obefazimod (ABX464) 正在评估用于溃疡性结肠炎和其他炎症性疾病。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Abivax</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 Abivax</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding ABVX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abivax SA Sponsored ADR (NASDAQ:ABVX - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有的 ABVX 吗？</strong> 访问 HoldingsChannel.com 获取 Abivax SA Sponsored ADR (NASDAQ:ABVX - 免费报告) 的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJWWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=ABVX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Abivax Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Abivax 吗？</h2>
</div><p>Before you consider Abivax, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Abivax 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abivax wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买... 而 Abivax 并不在名单上。</p>
</div><p>While Abivax currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Abivax 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Total Clarity Wealth Management Inc. Acquires Shares of 9,245 Abivax SA Sponsored ADR $ABVX

Market Beat

Abivax SA

2 倍做多纳斯达克生物技术 ETF - ProShares

美国制药 ETF - iShares

动态生物技术与基因组 ETF - Invesco

标普生物技术 ETF - SPDR

生物科技 ETF - VanEck Vectors

纽交所高增长板生物技术指数 ETF - First Trust

医药突破 ETF - ALPS

纳斯达克生物科技指数 ETF - iShares Nasdaq

第一地平线

美国银行

花旗

奥本海默控股

Jefferies Financial

FIRST HORIZON CORPORATION 6.50% DEP SHS REP 1/4000 PER PFD SER E

FIRST HORIZON CORPORATION DEP SHS REP 1/400 NON CUM PER PFD SER C

FIRST HORIZON CORPORATION DEP SHS REP 1/400 NON CUM PER PFD SER B

FIRST HORIZON CORPORATION DEP SH REP 1/4000 INT NON CUM PFD H WI

FIRST HORIZON CORPORATION DEP SHS REPSTG 1/4000TH PERP PFD SER F

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

CITIGROUP INC 6.250 NON CUM SER II PFD WI

Total Clarity Wealth Management Inc. 收购了 9,245 股 Abivax SA 赞助的美国存托凭证 $ABVX